Cullinan Oncology(US:CGEM)2026-03-10 11:26Financial Performance - The company reported total operating expenses of $241.6 million in 2025, an increase of 22.6% from $196.9 million in 2024[487]. - The net loss for 2025 was $219.9 million, compared to a net loss of $167.6 million in 2024, reflecting a 31.2% increase in losses year-over-year[487]. - The accumulated deficit as of December 31, 2025, was $588.1 million, indicating significant operating losses since inception[479]. - The net cash used in operating activities for 2025 was $175.8 million, compared to $145.3 million in 2024, indicating an increase in operational cash burn[499]. - The company reported a decrease in interest income to $22.2 million in 2025 from $29.7 million in 2024, a decline of 25.1%[487]. Cash and Investments - The company had cash, cash equivalents, and short-term investments totaling $377.9 million as of December 31, 2025[479]. - As of December 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $377.9 million, with long-term investments and interest receivable of $61.1 million[493]. - The company expects its current cash and investments to fund operations into 2029, although this is based on assumptions that may prove incorrect[494]. - The company completed a private placement in April 2024, raising net proceeds of $262.7 million after deducting offering costs of $17.3 million[496]. - The company has an at-the-market equity offering program allowing for the sale of up to $125.0 million of common stock, with $85.6 million remaining as of December 31, 2025[497]. Research and Development - Research and development expenses rose to $187.4 million in 2025, up from $142.9 million in 2024, primarily due to a one-time upfront in-licensing fee for velinotamig of $20 million[488]. - The ongoing Phase 1 OUTRACE Program for CLN-978 is expected to share initial clinical data in systemic lupus erythematosus and rheumatoid arthritis in Q2 2026 and Q3 2026, respectively[470]. - Zipalertinib is being evaluated in a pivotal Phase 2b trial, with a rolling submission for NDA seeking accelerated approval expected to be completed by February 2026[470]. - The company plans to begin enrolling dose expansion cohorts for CLN-049 in Q2 2026, with completion of enrollment expected by Q4 2026[470]. - Future funding requirements are expected to increase significantly due to ongoing research, development, and commercialization activities[505]. Licensing and Agreements - The company entered into a license agreement with Genrix in June 2025, paying an upfront fee of $20.0 million for the exclusive rights to develop and commercialize velinotamig[495]. - The company is eligible to receive up to $130.0 million in payments from Taiho upon U.S. regulatory approval of zipalertinib for specific cancer treatments[498]. Lease Obligations - Total future minimum lease payments as of December 31, 2025, were $3.1 million, with $1.0 million due within 12 months[509]. Regulatory and Compliance - The company is classified as a smaller reporting company and is not required to provide detailed market risk disclosures[520].